Zellexperimentell vergleichende Untersuchung zum Androgenrezeptor beim kastrationsresistenten Prostatakarzinom
comparative studies of the role of androgen receptor in castration-resistant prostate cancer
by Kerstin Meyer-Wilmes née Mösinger
Date of Examination:2020-06-30
Date of issue:2020-06-18
Advisor:Prof. Dr. Lutz Trojan
Referee:Prof. Dr. Günter Emons
Referee:Prof. Dr. Martin Oppermann
Files in this item
Name:2019-01-30_Druckversion DrArbeit Meyer-Wilme...pdf
Size:728.Kb
Format:PDF
Abstract
English
The androgen receptor plays an important role in the progression of prostate cancer to castration-resistant prostate cancer. In this stage of the disease the standard treatment of androgen deprivation therapy does not work anymore. So in this study we try to reveal how the androgen receptor could be affected by the influence of histone deacetylase inhibitor valproate in the VCaP cells. Androgen receptor RNA and androgen regulated genes were measured and compared to the results of stimulation with the antiandrogen bicalutamide. The aim is to reduce the androgen driven effects in the cancer cell or to even decrease the level of androgen receptors. With small interfering RNA it is possible to silence the protein of the androgen receptor in vitro. We did this also and could see that an effective down-regulation of the androgen receptor is only shown in the siRNA experiment. But with valproate some really interesting androgen inhibiting and antitumoral effects were exposed.
Keywords: castration resistant prostate cancer; androgen receptor; siRNA; valproate
Schlagwörter: kastrationsresistentes Prostatakarzinom; Valproat; siRNA; Androgenrezeptor